TOP HEADLINES

Featured Story

GSK wins asthma nod for blockbuster wannabe Breo

GlaxoSmithKline CEO Andrew Witty recently said slow-starting respiratory newcomer Breo was finally gaining some market traction. And now, it has a new asthma indication the company hopes can help speed things along.

One 'cultural difference' between Teva and Mylan? Coury's $22.5M pay wouldn't fly at Teva

Since before Teva even made its now-rejected $40 billion offer to buy Mylan, its target's exec chairman, Robert Coury, has been pretty down on the idea, citing a potential culture clash between the two companies. While Teva CEO Erez Vigodman has said he thinks they'd get along just fine, the rival drugmakers do have a few big differences between them--including their approach to executive compensation.

Small group of branded drugs like Nexium, Copaxone make up huge part of Medicare spend

It's a good thing for Medicare that AstraZeneca's Nexium has gone generic and Teva's Copaxone is headed that way. That is because they are among about 10% of the drugs covered by Medicare which account for about 25% of the cost.

GSK weighing scrapping investor payout to boost dividend instead

Analysts are suggesting that GlaxoSmithKline is thinking hard about scrapping a plan to reward investors by paying them about £4 billion and instead use money from its deals with Novartis to prop up its dividend, Reuters reports.

UPDATED: Big deal, small deal, any kind of good deal would help ready Pfizer for the Big Split

No one can pin down Pfizer CEO Ian Read when it comes to whether the company will split up--not publicly, anyway. That word won't come till late next year at least. But repeated questioning from analysts during the company's first-quarter earnings call did yield some facts in the matter.

MORE NEWS

From Our Sister Sites

FierceMedicalDevices

The head of the FDA's device arm (CDRH) acknowledged that the division is failing to live up to its vision that "patients in the U.S. have access to high-quality, safe, and effective medical devices of public health importance first in the world" because advanced devices like transaortic valve replacements are regularly approved in Europe 5 years earlier than the U.S, but cited statistics showing that CRDH has been getting devices to market faster in an April 30 address.

FierceMedicalDevices

Reuters takes a look at the technology revolution that's expected to enable the next step beyond wearables: devices that are so tiny and integrated with the human body that they are barely noticeable to the wearer or others.